Advertisement

Meyka AI - Contribute to AI-powered stock and crypto research platform
Meyka Stock Market API - Real-time financial data and AI insights for developers
Advertise on Meyka - Reach investors and traders across 10 global markets
Loading...

Pharma Mar, S.A.

PHMMFPNK
Healthcare
Biotechnology
$88.72
$0.00(0.00%)
U.S. Market opens in 9h 43m

Pharma Mar, S.A. Fundamental Analysis

Pharma Mar, S.A. (PHMMF) shows moderate financial fundamentals with a PE ratio of 38.40, profit margin of 19.02%, and ROE of 16.94%. The company generates $0.2B in annual revenue with strong year-over-year growth of 10.56%.

Key Strengths

PEG Ratio-2.37
Current Ratio2.73

Areas of Concern

No major concerns flagged.
We analyze PHMMF's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 70.6/100 based on profitability, valuation, growth, and balance sheet metrics. The B grade reflects solid fundamentals with room for improvement in valuation or growth.

Fundamental Health Score

B
70.6/100

We analyze PHMMF's fundamental strength across five key dimensions:

Efficiency Score

Weak

PHMMF struggles to generate sufficient returns from assets.

ROA > 10%
9.96%

Valuation Score

Moderate

PHMMF shows balanced valuation metrics.

PE < 25
38.40
PEG Ratio < 2
-2.37

Growth Score

Excellent

PHMMF delivers strong and consistent growth momentum.

Revenue Growth > 5%
10.56%
EPS Growth > 10%
22.46%

Financial Health Score

Excellent

PHMMF maintains a strong and stable balance sheet.

Debt/Equity < 1
0.25
Current Ratio > 1
2.73

Profitability Score

Excellent

PHMMF achieves industry-leading margins.

ROE > 15%
16.94%
Net Margin ≥ 15%
19.02%
Positive Free Cash Flow
Yes

Key Financial Metrics

Is PHMMF Expensive or Cheap?

P/E Ratio

PHMMF trades at 38.40 times earnings. This suggests a premium valuation.

38.40

PEG Ratio

When adjusting for growth, PHMMF's PEG of -2.37 indicates potential undervaluation.

-2.37

Price to Book

The market values Pharma Mar, S.A. at 6.62 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

6.62

EV/EBITDA

Enterprise value stands at 33.77 times EBITDA. This signals the market has high growth expectations.

33.77

How Well Does PHMMF Make Money?

Net Profit Margin

For every $100 in sales, Pharma Mar, S.A. keeps $19.02 as profit after all expenses.

19.02%

Operating Margin

Core operations generate 11.03 in profit for every $100 in revenue, before interest and taxes.

11.03%

ROE

Management delivers $16.94 in profit for every $100 of shareholder equity.

16.94%

ROA

Pharma Mar, S.A. generates $9.96 in profit for every $100 in assets, demonstrating efficient asset deployment.

9.96%

Following the Money - Real Cash Generation

Operating Cash Flow

Pharma Mar, S.A. produces operating cash flow of $21.00M, showing steady but balanced cash generation.

$21.00M

Free Cash Flow

Pharma Mar, S.A. produces free cash flow of $16.05M, offering steady but limited capital for shareholder returns and expansion.

$16.05M

FCF Per Share

Each share generates $0.93 in free cash annually.

$0.93

FCF Yield

PHMMF converts 1.26% of its market value into free cash.

1.26%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

38.40

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-2.37

vs 25 benchmark

P/B Ratio

Price to book value ratio

6.62

vs 25 benchmark

P/S Ratio

Price to sales ratio

7.21

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.25

vs 25 benchmark

Current Ratio

Current assets to current liabilities

2.73

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

0.17

vs 25 benchmark

ROA

Return on assets percentage

0.10

vs 25 benchmark

ROCE

Return on capital employed

0.08

vs 25 benchmark

How PHMMF Stacks Against Its Sector Peers

MetricPHMMF ValueSector AveragePerformance
P/E Ratio38.4029.45 Worse (Expensive)
ROE16.94%779.00% Weak
Net Margin19.02%-24936.00% (disorted) Strong
Debt/Equity0.250.26 Neutral
Current Ratio2.734.65 Strong Liquidity
ROA9.96%-19344.00% (disorted) Weak

PHMMF outperforms its industry in 2 out of 6 key metrics, particularly excelling in Net Margin, but lagging in P/E Ratio.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Pharma Mar, S.A.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

114.18%

Industry Style: Defensive, Growth, Innovation

High Growth

EPS CAGR

399.16%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

124.24%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ